Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4404 | blood sample for seroepidemiological investigation Wiki | 1.00 |
| drug1359 | Electroencephalogram with EKG lead Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to determine the prevalence of brainstem dysfunction in critically ill ventilated and deeply sedated patients hospitalized in the Intensive Care Unit (ICU) for a SARS-CoV-s2 infection.
Description: Clinical cranial nerves anomalies using validated scale (BRASS score- ranges from 0 to 7 - ) in deeply sedated patient (RASS <-3)
Measure: Brainstem dysfunction prevalence Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationDescription: Clinical cranial nerves anomalies using validated scale (BRASS score)
Measure: Brainstem dysfunction prevalence after sedation weaning Time: Day 4 to day 7 after sedation weaningDescription: Analysis of the sympathico-parasympathetic ratio (using spectral analysis of the EKG signal) according to the presence or absence of brainstem dysfunction and its severity
Measure: Link between brainstem dysfunction and clinical dysautonomia Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationnDescription: Analysis of the sympathico-parasympathetic ratio (using spectral analysis of the EKG signal) according to the presence or absence of brainstem dysfunction and its severity
Measure: Link between brainstem dysfunction and clinical dysautonomia after sedation weaning Time: 4 to 7 days after sedation weaningDescription: EEG power in delta, theta, alpha, beta and gamma frequency bands according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG power Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationDescription: EEG power in delta, theta, alpha, beta and gamma frequency bands according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG power after sedation weaning Time: Day 4 to day 7 after sedation weaning.Description: EEG functional connectivity using weighted Symbolic Mutual Information and weighted Phase Lag Index according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationDescription: EEG functional connectivity using weighted Symbolic Mutual Information and weighted Phase Lag Index according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG functional connectivity, after sedation weaning Time: Day 4 to day 7 after sedation weaning.Description: EEG complexity using Kolmogorov complexity and permutation entropy according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationDescription: EEG complexity using Kolmogorov complexity and permutation entropy according to the presence or absence of brainstem dysfunction and its severity
Measure: Characterization of brainstem dysfunction in COVID-19 patients: EEG complexity after sedation weaning Time: Day 4 to day 7 after sedation weaning.Description: Multivariate classification of the presence or absence of brainstem dysfunction using support vector machine and extra-trees algorithm based on the EEG derived quantitative features presented above
Measure: Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification Time: At inclusion or in patients with neuromuscular blockade 12h-72h following neuromuscular blocking agent cessationDescription: Multivariate classification of the presence or absence of brainstem dysfunction using support vector machine and extra-trees algorithm based on the EEG derived quantitative features presented above
Measure: Characterization of brainstem dysfunction in COVID-19 patients: multivariate classification after sedation weaning Time: Day 4 to day 7 after sedation weaning.Description: Using validated functional scale modified Rankin (mRankin) for independence assessment (mRankin ranges from 0 to 6 with higher scores indicating more severe disability)
Measure: Neurological functional evolution with mRankin Time: 90 days after inclusionDescription: Using validated functional scale Glasgow Outcome Scale Extended (GOSE) for independence assessment (GOSE ranges from 1 to 8 with higher scores indicating less severe disability outcome)
Measure: Neurological functional evolution with GOSE Time: 90 days after inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports